IBDEI0FA ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7012,2)
 ;;=^332807
 ;;^UTILITY(U,$J,358.3,7013,0)
 ;;=585.2^^31^420^2
 ;;^UTILITY(U,$J,358.3,7013,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7013,1,4,0)
 ;;=4^585.2
 ;;^UTILITY(U,$J,358.3,7013,1,5,0)
 ;;=5^CHR Kid Dis,Stage II
 ;;^UTILITY(U,$J,358.3,7013,2)
 ;;=^332808
 ;;^UTILITY(U,$J,358.3,7014,0)
 ;;=585.3^^31^420^3
 ;;^UTILITY(U,$J,358.3,7014,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7014,1,4,0)
 ;;=4^585.3
 ;;^UTILITY(U,$J,358.3,7014,1,5,0)
 ;;=5^CHR Kid Dis,Stage III
 ;;^UTILITY(U,$J,358.3,7014,2)
 ;;=^332809
 ;;^UTILITY(U,$J,358.3,7015,0)
 ;;=585.4^^31^420^4
 ;;^UTILITY(U,$J,358.3,7015,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7015,1,4,0)
 ;;=4^585.4
 ;;^UTILITY(U,$J,358.3,7015,1,5,0)
 ;;=5^CHR Kid Dis,Stage IV
 ;;^UTILITY(U,$J,358.3,7015,2)
 ;;=^332810
 ;;^UTILITY(U,$J,358.3,7016,0)
 ;;=585.5^^31^420^5
 ;;^UTILITY(U,$J,358.3,7016,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7016,1,4,0)
 ;;=4^585.5
 ;;^UTILITY(U,$J,358.3,7016,1,5,0)
 ;;=5^CHR Kid Dis,Stage V
 ;;^UTILITY(U,$J,358.3,7016,2)
 ;;=^332811
 ;;^UTILITY(U,$J,358.3,7017,0)
 ;;=V01.79^^31^421^6
 ;;^UTILITY(U,$J,358.3,7017,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7017,1,4,0)
 ;;=4^V01.79
 ;;^UTILITY(U,$J,358.3,7017,1,5,0)
 ;;=5^Viral Dis Contact
 ;;^UTILITY(U,$J,358.3,7017,2)
 ;;=^331577
 ;;^UTILITY(U,$J,358.3,7018,0)
 ;;=V01.89^^31^421^1
 ;;^UTILITY(U,$J,358.3,7018,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7018,1,4,0)
 ;;=4^V01.89
 ;;^UTILITY(U,$J,358.3,7018,1,5,0)
 ;;=5^Contact Other Comm Disease
 ;;^UTILITY(U,$J,358.3,7018,2)
 ;;=^328661
 ;;^UTILITY(U,$J,358.3,7019,0)
 ;;=V01.71^^31^421^4
 ;;^UTILITY(U,$J,358.3,7019,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7019,1,4,0)
 ;;=4^V01.71
 ;;^UTILITY(U,$J,358.3,7019,1,5,0)
 ;;=5^Varicella Contact/Exp
 ;;^UTILITY(U,$J,358.3,7019,2)
 ;;=^331576
 ;;^UTILITY(U,$J,358.3,7020,0)
 ;;=V01.79^^31^421^5
 ;;^UTILITY(U,$J,358.3,7020,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7020,1,4,0)
 ;;=4^V01.79
 ;;^UTILITY(U,$J,358.3,7020,1,5,0)
 ;;=5^Viral Dis Cont/Exp NEC
 ;;^UTILITY(U,$J,358.3,7020,2)
 ;;=^331577
 ;;^UTILITY(U,$J,358.3,7021,0)
 ;;=V01.83^^31^421^2
 ;;^UTILITY(U,$J,358.3,7021,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7021,1,4,0)
 ;;=4^V01.83
 ;;^UTILITY(U,$J,358.3,7021,1,5,0)
 ;;=5^E. Coli Contact/Exp
 ;;^UTILITY(U,$J,358.3,7021,2)
 ;;=^331578
 ;;^UTILITY(U,$J,358.3,7022,0)
 ;;=V01.84^^31^421^3
 ;;^UTILITY(U,$J,358.3,7022,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7022,1,4,0)
 ;;=4^V01.84
 ;;^UTILITY(U,$J,358.3,7022,1,5,0)
 ;;=5^Meningococcus Contact
 ;;^UTILITY(U,$J,358.3,7022,2)
 ;;=^331579
 ;;^UTILITY(U,$J,358.3,7023,0)
 ;;=250.00^^31^422^1
 ;;^UTILITY(U,$J,358.3,7023,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7023,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,7023,1,5,0)
 ;;=5^DM II w/o Complications
 ;;^UTILITY(U,$J,358.3,7023,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,7024,0)
 ;;=250.01^^31^422^2
 ;;^UTILITY(U,$J,358.3,7024,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7024,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,7024,1,5,0)
 ;;=5^DM I w/o Complications
 ;;^UTILITY(U,$J,358.3,7024,2)
 ;;=^331780
 ;;^UTILITY(U,$J,358.3,7025,0)
 ;;=250.40^^31^423^15
 ;;^UTILITY(U,$J,358.3,7025,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7025,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,7025,1,5,0)
 ;;=5^DM II w/Nephropathy
 ;;^UTILITY(U,$J,358.3,7025,2)
 ;;=^331795^583.81
 ;;^UTILITY(U,$J,358.3,7026,0)
 ;;=250.41^^31^423^5
 ;;^UTILITY(U,$J,358.3,7026,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7026,1,4,0)
 ;;=4^250.41
 ;;^UTILITY(U,$J,358.3,7026,1,5,0)
 ;;=5^DM I w/Nephropathy
 ;;
 ;;$END ROU IBDEI0FA
